Jan 10, 2023 / 11:00PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Great. Good afternoon, everyone. My name is Jess Fye, I'm a large cap biotech analyst at JPMorgan, and we are delighted to be continuing the conference today with BioCryst. A little bit of different format this year from years past. We're going to stay in this room for Q&A. If you have a question at the end of the presentation, just raise your hand, somebody you'll bring you a mic or you can submit them electronically as well.
So with that out of the way, let me turn it over to BioCryst's CEO, Jon Stonehouse.
Jon P. Stonehouse - BioCryst Pharmaceuticals, Inc. - CEO, President & Executive Director
Good afternoon. Thank you, Jess, for inviting us to this year's conference, and I was telling her before I got up here, I honestly can admit that I'm happy to be live in San Francisco. I didn't think I'd get to that point during COVID, but good to be here. I'm going to be making some forward-looking statements. Those statements have risks. The risk factors can be found in our
BioCryst Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers